Frank C.
- Country
- The Netherlands
- Department
- N/A
Research Overview
- Phase 3 Study of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
- A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)
- Phase 3 Randomized Trial of Pembrolizumab Versus Placebo in Stage IB-IIIA NSCLC Post-Resection and Adjuvant Therapy
Data & Insights
Has run more than one trial at 317 of 661 partner sites.
Specializations
Advanced Lung Cancer Treatment
This investigator specializes in treating non-small cell lung cancer (NSCLC) across various stages and presentations, with particular emphasis on advanced and metastatic cases.
- Early-stage NSCLC management post-surgery
- Metastatic non-squamous NSCLC therapy
- Advanced stage NSCLC treatment approaches
The investigator's work encompasses both early intervention and advanced disease management strategies.
Immunotherapy Applications
Focuses on innovative immunotherapeutic approaches in oncology, particularly investigating various immunotherapy combinations and comparative effectiveness.
- Combination immunotherapy protocols
- PD-1/PD-L1 inhibitor treatments
- Novel antibody therapies
Expertise extends to evaluating new immunotherapy agents and their combinations in treating lung cancer.
Respiratory Disease Management
Demonstrates expertise in treating chronic obstructive pulmonary disease (COPD) and related respiratory conditions.
- COPD therapeutic interventions
- Triple therapy optimization
- Chronic bronchitis treatment
The investigator explores advanced therapeutic options for managing chronic respiratory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.